7 alpha-hydroxy-4-cholesten-3-one has been researched along with carbostyril in 1 studies
| Studies (7 alpha-hydroxy-4-cholesten-3-one) | Trials (7 alpha-hydroxy-4-cholesten-3-one) | Recent Studies (post-2010) (7 alpha-hydroxy-4-cholesten-3-one) | Studies (carbostyril) | Trials (carbostyril) | Recent Studies (post-2010) (carbostyril) |
|---|---|---|---|---|---|
| 134 | 28 | 59 | 12,855 | 1,323 | 5,611 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berkers, G; Bodewes, FAJA; de Jonge, HR; Doktorova, M; Houwen, RHJ; Jonker, JW; van de Peppel, IP; Verkade, HJ | 1 |
1 other study(ies) available for 7 alpha-hydroxy-4-cholesten-3-one and carbostyril
| Article | Year |
|---|---|
IVACAFTOR restores FGF19 regulated bile acid homeostasis in cystic fibrosis patients with an S1251N or a G551D gating mutation.
Topics: Adolescent; Adult; Aminophenols; Bile Acids and Salts; Biological Availability; Child; Chloride Channel Agonists; Cholestenones; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Enterohepatic Circulation; Female; Fibroblast Growth Factors; Homeostasis; Humans; Male; Mutation; Netherlands; Quinolones | 2019 |